Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement, whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
147.2 USD | -1.91% | -2.45% | -23.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.10% | 18.59B | |
+48.67% | 56.69B | |
-2.76% | 41B | |
+38.11% | 38.11B | |
-11.22% | 26.89B | |
+9.25% | 25.59B | |
+1.88% | 12.39B | |
+26.43% | 11.99B | |
+21.74% | 11.88B | |
-10.54% | 10.89B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023